ClinicalTrials.gg
CompletedNCT06891638Updated May 8, 2026

Enhancing Reading Recovery in Aphasia With tDCS and Phonomotor Therapy

An interventional study of Schedule of tDCS administration in Stroke and Aphasia, sponsored by Kessler Foundation. Completed at 2 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Kessler Foundation · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
6
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study is designed for individuals with aphasia, a language disorder that affects many stroke survivors, making it difficult to read, speak, and understand language. Up to 70% of people with aphasia struggle with reading, which impacts their ability to communicate, work, and engage in daily life.

The study aims to test a new approach to reading rehabilitation by combining Phono-Motor Treatment (PMT), a language therapy adapted to improve reading, with transcranial direct current stimulation (tDCS), a safe and painless brain stimulation technique. tDCS delivers a mild electrical current to the brain, which may enhance learning. This study will assess whether adding tDCS to PMT improves reading therapy outcomes.

Read the detailed description

This study aims to improve reading rehabilitation for individuals with aphasia, a language disorder that affects many stroke survivors. The goal is to determine whether adding transcranial direct current stimulation (tDCS), a safe and painless brain stimulation technique, to Phono-Motor Treatment (PMT), a language therapy adapted for reading, enhances treatment effectiveness.

Participants will be randomly assigned to one of three treatment groups, each receiving different combinations of PMT and tDCS over six weeks. Some will receive active tDCS at different points in therapy, while others will receive a placebo (sham) version. By comparing how the timing of tDCS affects reading improvement, this study aims to optimize treatment strategies for individuals with aphasia.

Reading and language skills will be assessed before, during, and after treatment using standardized tests to measure progress. The study will take place at two sites: Kessler Foundation and the Medical College of Wisconsin (MCW), where participants will complete therapy sessions.

Findings from this research may help develop more effective and accessible treatments for stroke survivors with aphasia, improving their ability to read and communicate.

02

Conditions studied

  • Stroke
  • Aphasia

Keywords

  • Aphasia
  • Post-stroke rehabilitation
  • Reading impairment
  • Language therapy
  • Transcranial Direct Current Stimulation (tDCS)
  • Phonomotor Treatment (PMT)
  • Brain stimulation therapy
  • Neurorehabilitation
  • Randomized controlled trial (RCT)
  • Non-invasive brain stimulation
  • Neuromodulation
  • Speech and language therapy
03

In context

Stroke

8,255 studies on the registry are indexed under Stroke; 2,056 are open to participants now.

This study's enrollment of 6 is below the median of 49 across 6,024 interventional studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

Kessler Foundation is the lead sponsor of 175 studies on the registry; 61 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic (>6 months) left-hemisphere stroke
  • Aphasia diagnosis.
  • Deficits in reading aloud.

Exclusion criteria

Exclusion Criteria:

  • Eye condition not correctable with lenses and interfering with reading (e.g., blindness)
  • Severe apraxia of speech or cognitive deficits preventing participation.
  • Participation in one-on-one aphasia rehabilitation during the study period.
  • Brain disorders other than stroke (such as Alzheimer's Disease or Dementia, Parkinson's Disease, etc)
  • of tDCS or MRI

    • Skin condition affecting the scull (e.g., psoriasis) or open wounds at the stimulation site.
    • Presence of metallic implants (e.g., cardiac stimulators or pacemakers, cochlear implants)
    • History of ongoing/unmanaged seizers
    • Pregnancy
    • Claustrophobia
    • Inability to lie flat on the back
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Early tDCS

    This group will undergo Active tDCS + PMT for weeks 1-3 and Sham tDCS + PMT for weeks 4-6.

    Device: Schedule of tDCS administration

  • Sham comparator
    Late tDCS

    This group will undergo Sham tDCS + PMT for weeks 1-3 and Active tDCS + PMT for weeks 4-6.

    Device: Schedule of tDCS administration

  • Active comparator
    Interleaved tDCS

    This group will receive PMT + Active/Sham tDCS on alternate days for 6 weeks.

    Device: Schedule of tDCS administration

Interventions

  • DeviceSchedule of tDCS administration

    This study evaluates the combined effects of Phono-Motor Treatment (PMT) and transcranial direct current stimulation (tDCS) for reading rehabilitation in post-stroke aphasia. Unlike standard speech therapy, this intervention integrates non-invasive brain stimulation to enhance language recovery by modulating neural activity in perilesional areas. We hypothesize that active tDCS will enhance PMT efficacy, leading to greater improvements in reading competence and phonological processing compared to sham tDCS. Through systematic testing across the 3 study arms, we expect to identify the most effective stimulation timing.

06

What researchers measure

Primary outcomes

  1. Reading aloud accuracy

    Participants will read words and pronounceable pseudowords that appear one at a time on the computer screen. Each testing session will be audio recorded and independently scored by 2 raters, with ties resolved by a 3rd rater.

    Time frame: before treatment, midway through treatment, and immediately after treatment

Secondary outcomes

  1. Reading Comprehension Battery for Aphasia 2nd Edition

    Participants will complete a standardized language assessment.

    Time frame: before treatment, midway through treatment, and immediately after treatment

  2. Western Aphasia Battery

    Participants will complete a standardized language assessment.

    Time frame: before treatment, midway through treatment, and immediately after treatment

07

Study locations

2 sites
  • Kessler Foundation
    West Orange, New Jersey 07052, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06891638
Lead sponsor
Kessler Foundation
Responsible party
Olga Boukrina (Assistant Director, Center for Stroke Rehabilitation Research, Kessler Foundation) — Principal investigator
First posted
Mar 24, 2025
Start date
May 12, 2025
Primary completion
Feb 14, 2026
Completion
Feb 14, 2026
Last update
May 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion